Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Navigators, Reminders May Improve Follow-Up After Positive Fecal Blood Test

October 12, 2017
By Leah Lawrence
Article

Follow-up intervention by patient navigators or provider reminders may help to improve the number of patients who undergo colonoscopy after positive fecal blood test results.

Follow-up intervention by patient navigators or provider reminders may help to improve the number of patients who undergo colonoscopy after positive fecal blood test results, according to the results of a review published in Annals of Internal Medicine.

“Timely diagnostic colonoscopy after a positive fecal test result is a critical step on the colorectal cancer screening continuum,” wrote Kevin Selby, MD, of Kaiser Permanente Division of Research in Oakland, California, and colleagues. “Although research has primarily focused on screening completion, fecal testing will not be effective if positive results are not followed.”

With this review, Selby and colleagues evaluated interventions that could improve follow-up rates after positive fecal blood tests. They reviewed 23 studies that reported data from an intervention for colonoscopy follow-up of asymptomatic adults with positive fecal test results. The studies included seven randomized and 16 nonrandomized studies.

Much of the research was of low-quality, the researchers noted, particularly with regard to system-level interventions, such as automated referral, patient registries, and quality improvement efforts. However, the study did reveal moderate evidence that supported the implementation of patient- and provider-level interventions.

The evidence suggested that the use of patient navigators, or individuals who work with patients to counsel and guide them through the barriers associated with cancer care, can increase rates of follow-up colonoscopy. The review included five studies of patient navigation interventions. One study compared usual care with or without the addition of a registered nurse patients navigator. Use of a navigator to help with logistic barriers and to conduct motivational interview resulted in a non-significant but clinically relevant increase in the number of patients completing colonoscopies.

“Patient navigators can provide one-on-one education and individualized reduction of structural barriers,” the researchers wrote. “Cost may be a limiting factor, however: An economic evaluation concluded that patient navigation for the follow-up of abnormal results on cancer screening tests costs an additional $275 per patient (CI, $260 to $290).”

Provider-level interventions that utilize electronic reminders to alert physicians of patients who have not taken adequate action after a positive test result were shown to improve colonoscopy completion from 9 to 25 percentage points.

Based on these results, the researchers concluded that “more research is needed given the critical role of the diagnostic resolution of positive test results in fecal blood-based screening.”

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content
Advertisement

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Russ Conroy
August 7th 2025
Article

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

Roman Fabbricatore
July 30th 2025
Article

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.


Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.

Related Content
Advertisement

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.

TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

Russ Conroy
August 7th 2025
Article

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well-tolerated, with no unexpected toxicities observed.

Onvansertib Exhibits Encouraging Responses in RAS-Mutant Metastatic CRC

Roman Fabbricatore
July 30th 2025
Article

Phase 2 CRDF-004 results revealed that the addition of onvansertib to chemotherapy/bevacizumab was well tolerated, with no unexpected toxicities observed.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.


Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.